Leadership2 distinct publishers3 min readPublished
The new BMJ cohort counts confirmed cases against every NFL decedent, which makes 25% arithmetic and everything above it argument. That distinction is what liability models will run on.
The Board Room · Leadership desk
Compiled by The Board RoomSomething wrong?How this is made
The quarter is not an estimate. Of the 878 former NFL players who died between 2016 and 2021, the investigators had pathology on 235, about 27 percent of the cohort [5][1]. Vox's newsletter account puts the in-window examined count at 235; the full-period donation total reported elsewhere is 338, at a 93 percent positivity rate [c6b][6]. Apply that rate to the in-window subset and you get roughly 219 confirmed cases, or 24.9 percent of everyone who died in those six years [3]. The headline figure is confirmed disease divided by all decedents, which is why it behaves like a floor rather than a central estimate.
Everything contested sits in the 643 brains nobody examined [2]. The paper's own bound runs to about 97 percent if every non-donor except the 20 definitively cleared brains had the disease [7]; the authors allow that the real rate may be near 90 percent [19]; the 2019 Binney and Bachynski modelling exercise put it closer to 10 percent [9]. Donation is symptom-driven and non-random [10], so the ceiling is as much an artifact of who volunteers as the floor is of who does not.
For anyone pricing physical risk, the floor is the usable number precisely because selection bias cannot inflate a count. It sits over a near-complete roster of every man to play a game since 1949 and a national vital-statistics denominator [3], and it is conservative in a specific way: another 215 non-donors had a neurodegenerative disease listed on the death certificate, on a document type that undercaptures those diagnoses [11].
The defence material is in the same paper. Dementia showed up in more than 90 percent of stage IV cases, but also in roughly 40 percent of donors whose brains were clear of CTE, with weak correlation at lower stages [8]. Uzma Samadani, a neurosurgeon who consulted for the NFL from 2015 to 2019, warns against repeating the amyloid hypothesis and treating mislocalized tau as proven cause of symptoms [13]. A defendant can concede a 25 percent pathology rate and still contest causation in any individual case.
Then there is vintage. Mean age at death among donors was about 66, so most careers ended before 2005, ahead of helmet grading, kickoff redesign, targeting enforcement and contact-practice limits [12]. Vox's newsletter reaches for black lung as the analogy [15], but black lung came with an exposure standard; the closest regulatory move here runs the other way, OSHA having proposed excluding hazards inherent and inseparable from the core nature of a professional activity, a proposal not yet finalised [14]. Meanwhile the labour supply thins while demand does not: tackle participation among 13-to-17-year-olds fell 9 percent from 2019 to 2024 and now trails tennis [16], while NFL games were 83 of last year's 100 top-rated television programmes [18].
Both the league and the plaintiffs' bar can quote this study accurately and land in opposite places, because a 72-point interval is wide enough to hold both readings [5].
Ranked by verification strength, evidence, and original report placement.
Placed over the population denominator, the donor findings yield a minimum prevalence at death of roughly 25% for the 2016-2021 cohort, with a theoretical ceiling of about 97% assuming every non-donor had the disease except the 20 brains definitively cleared.
A retrospective population-based cohort was published in The BMJ by Daneshvar and colleagues at Mass General Brigham, Boston University and the Concussion & CTE Foundation.
The study examined the brains of 235 of the 878 former NFL players who died between 2016 and 2021.
Among the more than 330 NFL brains donated across the full period, 93% showed CTE.
Among the 338 players whose brains were donated and studied, the CTE rate was 93%.
Brain donation is symptom-driven and non-random, which inflates any brain-bank numerator, and the resulting 25%-97% interval is honest but not clinically accurate for counselling any individual player.
Follow any of these and your For You feed starts watching them — no settings page required.
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Strong design, wide bound
The underlying work is a peer-reviewed population-based cohort with a near-complete roster since 1949, a national vital-statistics denominator, an explicit bounding analysis, and disclosed selection-bias limits, which is a structural improvement on donor-only series and on the 2019 modelling baseline. It falls short of decisive because only 235 of 878 in-window decedents were examined, the published interval spans 72 percentage points, death certificates undercapture neurodegenerative diagnoses, and the pathology-to-symptom link is explicitly weak below stage IV.
Behaviour shifting, institutions static
Downstream uptake is real but one-sided. Household behaviour is already moving: teen tackle participation is down 9% since 2019 and now trails tennis, tackle play among 6-12s is down 7%, and flag football is up 13.6% with league investment behind it. Consumption has not moved -- NFL games were 83 of the top 100 rated shows, up from 72 -- and institutional response is unresolved, with the only cited regulatory action an unfinalised OSHA proposal that would exclude inherent hazards from enforcement rather than address them.
Ceiling talk outruns the floor
Mildly overstated relative to what the cohort establishes. The defensible result is a 25% floor with a 97% theoretical ceiling, yet coverage circulates a possible ~90% true rate and 'most players' framing, repeating the pattern that turned the 2017 110-of-111 donor series into a purported prevalence figure. Working against inflation: the study itself is conservative (215 non-donors had neurodegenerative diagnoses on undercapturing certificates), one publisher documents the caveats in detail, and a named expert's causation caution is on record, so the gap is moderate rather than severe.
Disclosed stakes on both readings
Material interests sit on both sides of the interpretation and are largely disclosed in the sources. The dissenting expert is identified as a 2015-2019 NFL consultant and founder of a concussion-diagnostics company with an FDA-cleared product. The research consortium includes the brain bank and a CTE foundation whose case-finding depends on donation. The league is funding the flag football format that its own participation data show growing, and one publisher's author writes as a self-described lifelong football fan while its newsletter argues an occupational-regulation frame. Ratings dominance gives broadcasters and the league direct financial exposure to how the number is read.
Solid on the floor, thin above it
Three independent articles across two publishers agree on the study, the 93% donor rate, and the at-least-25% conclusion, and the arithmetic reconciles (93% of 235 examined brains is about 24.9% of 878). Confidence drops for anything above the floor: the ~90% figure rests on one source, only one publisher documents the methodological limits, participation and OSHA facts are each single-sourced, and the cluster contains no independent verification beyond the reporting itself.
science
US life expectancy hit 79 in 2024, and the cushion over 2019 is about 73 days1 distinct publisher
product
Firmus buys the factory that makes its HyperCube: AU$300m for sheet metal, not silicon1 distinct publisher
leadership
DARPA's SHINE program shifts military brain money from detection to rewiring1 distinct publisher
product
Three Salmonella Outbreaks, One Failure Mode: Nobody Knew Where the Ingredient Went1 distinct publisher
Distinct publishers with included, body-backed reporting in this cluster.
forbes.com
1 article · August 25, 2026
vox.com
2 articles · August 25, 2026